Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Chugai to Construct New Synthetic Research Building at Ukima Lab
July 30, 2018
- Chugai to Extend Operation Period of Singapore Research Subsidiary
July 30, 2018
- AI in Pharma - 1: Companies Going Digital in Sales Support but Still Embrace Rep Experience
July 30, 2018
- Chugai Filed Tecentriq for 1st Line Lung Cancer in March as Players Race to Grab Low PD-L1 Expressers
July 27, 2018
- Chugai Sees Solid Uptake for Tecentriq, Hemlibra but CEO Frets Pricing Stability
July 27, 2018
- Dasotraline Demonstrates Significant Improvement in Binge Eating Disorder in US PIII Study: Sunovion
July 27, 2018
- Elenbecestat Clears Brain Amyloid, Eisai/Biogen Reports Detailed PII Data
July 26, 2018
- Alunbrig Beats Xalkori in Front-Line NSCLC: Takeda
July 26, 2018
- (Update) Eisai/Biogen Alzheimer’s Drug BAN2401 Slows Cognitive Decline by 30%
July 26, 2018
- Astellas Is Best Pharma Company to Work for: Survey
July 26, 2018
- 2 Major Japan Wholesalers Hook Up on Specialty, Generic Drug Biz
July 25, 2018
- Solasia Grabs China Approval for Antiemetic Patch Drug
July 25, 2018
- Oncologist Lauds Imfinzi as Trailblazer in Stage III Lung Cancer, Eagerly Awaiting OS Data
July 24, 2018
- Sales Reps Required Spontaneous Safety Reports even in Surveys Using Database: Ms Takizawa of Otsuka
July 24, 2018
- Shionogi Ups Earnings Outlook on Xofluza Boost
July 24, 2018
- Daiichi Sankyo’s Herceptin Biosimilar Might Hit Market as Early as November, Breast Cancer Use Also Eyed
July 23, 2018
- Maruho to Increase Information Supply to Non-Dermatologists Using Digital Technology
July 23, 2018
- Wakamoto to Initiate PIII Study of Treatment for Ocular Hypertension
July 23, 2018
- J-TEC Submits Trial Protocol for Autologous Cultured Cartilage in Knee Osteoarthritis Use
July 20, 2018
- Toray, Bonac to Begin US PI Trial of Nucleic Acid for IPF
July 20, 2018
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…